A placebo-controlled trial of the effects of hydrochlorothiazide on nocturnal enuresis.

Autor: Alawwa IA; Nephrology Section, Jordan University Hospital, Jordan University, Amman, Jordan. i.alawwa@ju.edu.jo, Matani YS, Saleh AA, Al-Ghazo MA
Jazyk: angličtina
Zdroj: Urologia internationalis [Urol Int] 2010; Vol. 84 (3), pp. 319-24. Date of Electronic Publication: 2010 Apr 13.
DOI: 10.1159/000288236
Abstrakt: Objective: To assess the efficacy, tolerability and side effects of the diuretic hydrochlorothiazide (HCTZ) in the management of monosymptomatic nocturnal enuresis by a placebo-controlled double-blind crossover trial.
Patients and Methods: Forty patients suffering from nocturnal enuresis were blindly randomized into 2 groups of equal numbers. Group 1 first received placebo for 3 months, and group 2 received oral HCTZ once daily for the same period. Both groups, after a 2-week wash-out period, were crossed over in their medication and continued treatment for another 3 months. The main outcome measure (variable) for the assessment of drug efficacy was taken to represent the average reduction in the percentage of wet nights as compared to the baseline enuresis pattern. Statistical analysis was based on a t test (p Results: Both HCTZ and placebo were statistically effective in reducing the average percentage of wet nights. HCTZ resulted in a significantly better reduction than placebo (41.1 vs. 32.5%; p Conclusion: The use of HCTZ in the treatment of nocturnal enuresis has never been previously evaluated. The drug, in this pilot study, has a promising statistical superiority to placebo. Its clinical value, however, deserves further definition in future controlled trials.
(Copyright 2010 S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz: